Oct 2026· Cancers· Vol 18· 0 citations· 40 references
Medicine
TL;DR
The feasibility of applying the 2021 World Health Organization Classification of Tumors of the Central Nervous System (WHO CNS5) to adult diffuse gliomas in Colombia was evaluated, and female sex was associated with longer survival in unadjusted analysis.
Abstract
Simple Summary This study evaluated the feasibility of applying the 2021 World Health Organization Classification of Tumors of the Central Nervous System (WHO CNS5) to adult diffuse gliomas in Colombia. We retrospectively analyzed 68 patients treated at two referral hospitals in Bogotá between 2015 and 2023. A sequential molecular workflow using immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), polymerase chain reaction (PCR), and Sanger sequencing was used to support diagnostic reassessment. The diagnosis changed in 51.5% of cases, particularly among tumors initially classified as astrocytoma or glioma, not otherwise specified (NOS). The proportion classified as glioblastoma increased from 48.5% under the historical histologic classification to 66.2% under the study’s WHO CNS5-based algorithm, while FISH-defined oligodendrogliomas decreased from 17.6% to 11.8%. Overall survival differed across historical histologic groups (p = 0.03), whereas differences across the WHO CNS5-based groups were not statistically significant (p = 0.13). Female sex was associated with longer survival in unadjusted analysis, while age was the only independent predictor in the multivariable model. Because comprehensive sequencing and systematic +7/−10 testing were not performed, these findings should be interpreted as an exploratory assessment of diagnostic feasibility rather than complete molecular ascertainment or evidence of treatment benefit.
The near-absence of molecular results means the large majority of diffuse gliomas cannot be fully classified by current WHO standards, a concrete diagnostic-capacity gap with direct implications for prognostication, treatment stratification, and trial eligibility.
Suleiman S. Daoud, Atef F. Hulliel, Sultan Jarrar et al.· Frontiers in Oncology· 0 citations
The logistic strategy achieved high sensitivity and discrimination for identifying mGBM according to CNS WHO 2021 and demonstrated more consistent calibration across observers, which support the further evaluation of the tool, particularly in radiologically atypical mGBM.
Yousif Aldabbagh, F. Bhatti, Nitin Menon et al.· Frontiers in Oncology· 0 citations
Background: Atypical meningiomas (CNS WHO grade 2) are biologically heterogeneous, and reliable preoperative imaging correlates of tumor biology remain incompletely defined. This study investigated associations between routinely acquired conventional MRI features and histopathological markers of biological aggressivene...
Hikmet Turan Suslu, Halit Alioğlu, Serife Altunbay et al.· Journal of Clinical Medicine· 0 citations
Background and Objectives: Diffuse midline glioma (DMG), H3 K27-altered, occurs in children and adults, but age-group differences and their prognostic significance remain uncertain. We examined clinicopathologic and molecular features and survival in H3 K27M-mutant DMG across age groups. Materials and Methods: This ret...
B. Lee, H. Kim, H. Lee et al.· Medicina· 0 citations
The 2021 World Health Organization (WHO) Classification of Tumors of the Central Nervous System requires molecular alterations for the integrated diagnosis of diffuse gliomas but the necessity of comprehensive genomic profiling in routine practice remains uncertain. We retrospectively evaluated a practical molecular di...
Y. Shiba, Kosuke Aoki, F. Ohka et al.· Journal of Neuropathology an...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.